Introduction {#s1}
============

Circulating glucocorticoids exert potent metabolic effects, including lipolysis, hepatic gluconeogenesis, amino acid mobilization, and reduced skeletal muscle glucose uptake ([@B1]). This is facilitated by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11B1), which (re)activates glucocorticoid in a tissue-specific manner to determine bioavailability ([@B2]). As such, states of glucocorticoid excess (e.g., Cushing syndrome) are prodiabetic because they cause profound glucose intolerance and insulin resistance.

Although systemic administration of glucocorticoids induces a compensatory increase in β-cell mass and eventually insulin secretory failure as a result of insulin resistance ([@B3]), effects directly on β-cell function are less well understood. Suggesting an important link between glucocorticoids and insulin release, β-cell--specific glucocorticoid receptor (GR) overexpression reduces glucose tolerance ([@B4]). However, in vitro studies that used isolated islets have shown inhibitory or no effect of glucocorticoids on glucose-stimulated insulin secretion, depending on the steroid potency, concentration, and treatment duration ([@B5]--[@B9]). By contrast, HSD11B1 increases ligand availability at the GR by converting less-active to more active glucocorticoid (11-dehydrocorticosterone (11-DHC)→corticosterone in rodents; cortisone→cortisol in man), impairing β-cell function in islets both in vitro and in vivo ([@B6],[@B10],[@B11]). Whereas 11-DHC has consistently been shown to impair β-cell function in islets from obese animals, conflicting reports exist about its effects on normal islets ([@B7],[@B10]).

More generally, the signaling components targeted by glucocorticoids are not well defined. Although exogenous application of glucocorticoid subtly decreases insulin release and NADP, cAMP, and inositol phosphate production ([@B5]), these studies were performed by using high-dose dexamethasone (25× relative potency compared with cortisol). Conversely, administration of the same glucocorticoid in drinking water augments insulin release by increasing the number of docked exocytotic vesicles as well as β-cell mitochondrial potential/metabolism ([@B12]). However, indirect effects of insulin resistance cannot be excluded because studies in high-fat diet--fed mice have shown that compensatory β-cell responses, including proliferation, occur within a few days ([@B13]). Furthermore, glucocorticoid administration or GR deletion in the early neonatal period alters β-cell development, leading to reductions in the expression of key maturity markers, including Pdx1, Nkx6.1, and Pax6 ([@B14],[@B15]). Whether this is also seen in adult islets, as may occur during diabetes ([@B16]), is unknown.

In the current study, we investigated the mechanisms by which the endogenous glucocorticoids corticosterone and cortisol affect β-cell function. By using in situ imaging approaches together with biosensors, we reveal that glucocorticoids perturb cytosolic Ca^2+^ concentration through effects on voltage-dependent Ca^2+^ channel (VDCC) function without altering β-cell maturity, glucose-induced changes in the ATP/ADP ratio, or incretin responsiveness. This, however, does not reduce insulin secretion because glucocorticoids upregulate parallel cAMP signaling pathways. The less-active glucocorticoids 11-DHC and cortisone show identical effects, which could be reversed in mouse after global deletion of *Hsd11b1*. Thus, a steroid-regulated feedback loop encompassing an enzymatic amplification step maintains normal insulin secretory output in the face of impaired β-cell ionic fluxes.

Research Design and Methods {#s2}
===========================

Animals {#s3}
-------

CD1 mice (8--12 weeks old, male) were used as wild-type tissue donors. *Hsd11b1*^−/−^ mice were generated as previously described ([@B17]). Studies were regulated by the Animals (Scientific Procedures) Act 1986 of the U.K., and approval was granted by the University of Birmingham's Animal Welfare and Ethical Review Body.

Islet Isolation {#s4}
---------------

Islets were isolated by using collagenase digestion and cultured in RPMI medium supplemented with 10% FCS, 100 units/mL penicillin, and 100 μg/mL streptomycin. Vehicle (ethanol 0.2%), 11-DHC (20/200 nmol/L), or corticosterone (20 nmol/L) (i.e., within the circulating free glucocorticoid range) were applied for 48 h. BSA-conjugated palmitate was applied at 0.5 mmol/L.

Human Islet Culture {#s5}
-------------------

Islets were obtained from isolation centers in Alberta (Alberta Diabetes Institute IsletCore), Canada ([@B18]), and Pisa and Milan, Italy, with local and national ethical permission. Islets were cultured in RPMI medium containing 10% FCS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone; supplemented with 5.5 mmol/L [d]{.smallcaps}-glucose; and treated with either vehicle (ethanol 0.2%), cortisone (200 nmol/L), or cortisol (20 nmol/L) for 48 h. See [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1) for donor characteristics. Studies were approved by the National Research Ethics Committee (REC reference 16/NE/0107, Newcastle and North Tyneside, U.K.).

Calcium, ATP/ADP, and cAMP Imaging {#s6}
----------------------------------

Islets were loaded with 10 μmol/L Fluo8 AM for 45 min at 37°C before washing and incubation in buffer for another 30 min to allow cleavage by intracellular esterase. Imaging was conducted by using either *1*) a CrestOptics X-Light spinning disk and 10×/0.4 numerical aperture (NA) objective or *2*) a Zeiss LSM 780 confocal microscope and 10×/0.45 NA objective. For the CrestOptics system, excitation was delivered at λ = 458--482 nm (400-ms exposure, 0.33 Hz) and emitted signals detected at λ = 500--550 nm by using an electron-multiplying charge-coupled device (Photometrics). For the Zeiss system, excitation was delivered at λ = 488 nm and emitted signals detected at λ = 499--578 nm by using a photomultiplier tube. Fura2 was loaded as for Fluo8, and imaging was performed by using light-emitting diodes (excitation λ = 340/385 nm, emission λ = 470--550 nm).

ATP/ADP ratios and cAMP responses were measured by using adenovirus harboring either Perceval (excitation/emission as for Fluo8) or the fluorescence resonance energy transfer (FRET) probe, exchange protein directly activated by cAMP 2 (Epac2)-camps (excitation λ = 430--450 nm; emission λ = 460--500 nm and 520--550 nm) ([@B19],[@B20]). For Perceval, glucose was increased from 3 to 11 mmol/L, which leads to plateau responses ([@B21]). An effect of glucocorticoid on Epac2-camps expression was unlikely because single- and dual-channel fluorescence under maximal stimulation was similar for all treatments ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). In all cases, HEPES-bicarbonate buffer was used, containing (in mmol/L[)]{.smallcaps} 120 NaCl, 4.8 KCl, 24 NaHCO~3~, 0.5 Na~2~HPO~4~, 5 HEPES, 2.5 CaCl~2~, 1.2 MgCl~2~, and 3--17 [d]{.smallcaps}-glucose. Ca^2+^, cAMP, and ATP/ADP traces were normalized as F / F~min~, where F is fluorescence at any given time point and F~min~ is minimum fluorescence during the recording (i.e., under basal conditions).

Electrophysiology {#s7}
-----------------

VDCC currents were recorded from dispersed mouse β-cells as previously described ([@B22]). Patch electrodes were pulled to a resistance of 3--4 MΩ then filled with an intracellular solution containing (in mmol/L) 125 CsCl, 10 tetraethylammonium Cl, 1 MgCl~2~, 5 EGTA, 10 HEPES, 3 MgATP, pH 7.22 with CsOH. Cells were patched in HEPES-buffered solution + 17 mmol/L glucose. Upon obtaining the whole-cell configuration with a seal resistance \>1 GΩ, the bath solution was exchanged for a modified HEPES-buffered solution containing (in mmol/L) 62 NaCl, 20 tetraethylammonium Cl, 30 CaCl~2~, 1 MgCl~2~, 5 CsCl, 10 HEPES, 17 glucose, 0.1 tolbutamide, pH 7.35 with NaOH. β-Cells were perfused for 3 min with this solution before initiating the VDCC recording protocol. Voltage steps of 10 mV were applied from a holding potential of −80 mV; linear leak currents were subtracted online by using a P/4 protocol. Data were analyzed by using Clampfit software (Molecular Devices).

Immunohistochemistry and Superresolution Imaging {#s8}
------------------------------------------------

Islets were fixed overnight at 4°C in 4% formaldehyde before immunostaining with rabbit monoclonal anti-insulin (1:400; Cell Signaling Technology) and goat anti-rabbit Alexa Fluor 568 (1:1,000). Superresolution imaging was performed by using a VT-iSIM system (VisiTech International) and 100×/1.49 NA objective. Excitation was delivered at λ = 561 nm, and emitted signals were captured at λ = 633--647 nm by using an sCMOS camera. Image stacks were cropped to include only the near-membrane regions and exclude out-of-focus signal and converted to 8-bit gray scale before obtaining the maximum intensity projection. Auto thresholding was performed in Fiji (National Institutes of Health) to produce a binary snapshot from which the area occupied by insulin granules could be quantified as a unitary ratio (V/v) versus the total membrane area by using the analyze particle plug-in as previously described ([@B20]).

Real-time PCR {#s9}
-------------

Relative mRNA abundance was determined by using SYBR Green chemistry, and fold change in mRNA expression was calculated compared with *Actb* by using the 2^--ΔΔCt^ method (see [Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1) for primer sequences). *Hsd11b1* mRNA abundance was determined by using TaqMan assays for mouse (cat. \#4331182) and human (cat. \#4331182) tissue, *Hsd11b1* expression was calculated by using 2^--ΔCt^ × 1,000, and transformed values are presented as arbitrary units.

Measurements of Insulin Secretion and ATP in Isolated Islets {#s10}
------------------------------------------------------------

Batches of eight islets were placed in low-bind Eppendorf tubes and incubated for 30 min at 37°C in HEPES-bicarbonate buffer containing 3 mmol/L glucose before the addition of either 3 mmol/L glucose, 17 mmol/L glucose, or 17 mmol/L glucose + 10 mmol/L KCl for another 30 min and collection of supernatant. Total insulin was extracted into acid ethanol. Insulin concentration was determined by using an HTRF (homogeneous time-resolved fluorescence)-based assay (Cisbio) according to the manufacturer's instructions. Total ATP at 3 and 17 mmol/L glucose was measured in batches of 25 islets by using a luciferase-based assay (Invitrogen), and values were normalized to total protein.

Statistical Analyses {#s11}
--------------------

Pairwise comparisons were performed with paired or unpaired Student *t* test. Interactions among multiple treatments were determined by one-way ANOVA (adjusted for repeated measures as necessary) followed by Bonferroni or Tukey post hoc test. Analyses were conducted by using GraphPad Prism and Igor Pro software.

Results {#s12}
=======

Glucocorticoids Alter Ionic but Not Metabolic Fluxes {#s13}
----------------------------------------------------

Fluo8-loaded β-cells residing within intact islets of Langerhans were subjected to multicellular Ca^2+^ imaging approaches ([@B23]). Individual β-cells responded to elevated glucose (3 mmol/L→17 mmol/L) with large increases in cytosolic Ca^2+^ levels ([Fig. 1*A* and *B*](#F1){ref-type="fig"}). Whereas 11-DHC 20 nmol/L was without effect, higher (200 nmol/L) concentrations suppressed the amplitude and area under the curve (AUC) of Ca^2+^ rises in response to glucose and glucose + 10 mmol/L KCl by ∼30% ([Fig. 1*A*--*E*](#F1){ref-type="fig"} and [Supplementary Figs. 1*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1) and [2*A*--*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), and this reached ∼50% in the presence of corticosterone 20 nmol/L. Results were confirmed by using the ratiometric Ca^2+^ indicator Fura2, excluding a major contribution of basal Ca^2+^ levels to the magnitude changes detected here ([Supplementary Fig. 2*A*--*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). No effect of glucocorticoid on the time to onset of Ca^2+^ rises was detected (lag period ± SD 22.5 ± 7.7 vs. 26.3 ± 9.7 vs. 24.0 ± 6.2 s for control, 11-DHC, and corticosterone, respectively; nonsignificant by one-way ANOVA). The peak Ca^2+^ response to KCl depolarization in low (3 mmol/L) glucose was unaffected by 11-DHC and significantly increased by corticosterone ([Supplementary Fig. 2*D* and *E*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), although both glucocorticoids reduced Ca^2+^ amplitude when KCl concentration was increased from 10 to 30 mmol/L ([@B24]) ([Supplementary Fig. 2*F* and *G*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). Although both 11-DHC and corticosterone led to more sustained Ca^2+^ influx in response to 3 mmol/L glucose + 10 mmol/L KCl ([Supplementary Fig. 2*E*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), this was not the case with 30 mmol/L KCl ([Supplementary Fig. 2*G*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). An effect of treatment on basal Ca^2+^ levels at 3 mmol/L glucose was unlikely because the Fura2 340/385 ratio was not significantly affected by 11-DHC or corticosterone ([Supplementary Fig. 2*H*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)).

![Glucocorticoids suppress cytosolic Ca^2+^ fluxes in response to glucose and glucose + KCl. *A*: Mean ± SEM intensity-over-time traces showing glucose- and glucose + KCl--stimulated Ca^2+^ rises in mouse islets treated for 48 h with 11-DHC or corticosterone (*n* = 14--28 islets from six animals). *B*: Representative maximum intensity projection images showing impaired Ca^2+^ signaling in glucose-stimulated islets treated with control, 200 nmol/L of 11-DHC, and corticosterone (scale bar = 20 μm) (images cropped to show a single islet). *C*: Summary bar graph showing a significant reduction in the amplitude of glucose-stimulated Ca^2+^ rises after treatment with either glucocorticoid (*n* = 14--28 islets from six animals). *D*: As for *C*, but AUC. *E*: As for *C*, but glucose + KCl. *F*: Corticosterone and 11-DHC significantly decrease Ca^2+^ spiking frequency at high glucose (representative traces shown) (*n* = 14 islets from three animals). *G*: As for *F*, but summary bar graph showing Ca^2+^ oscillations per minute. *H*: Cortisone 200 nmol/L and cortisol 20 nmol/L blunt glucose- and glucose + KCl--stimulated Ca^2+^ rises in human islets (representative traces shown) (*n* = 15--18 islets from three donors, 48 h). *I* and *J*: As for *H*, but summary bar graphs showing amplitude of Ca^2+^ responses to glucose (*I*) and glucose + KCl (*J*). *K*: 11-DHC and corticosterone do not affect Ca^2+^ responses to the incretin mimetic exendin-4 (Ex4) 10 nmol/L (representative traces shown) (*n* = 14--17 islets from three animals). *L* and *M*: As for *K*, but summary bar graphs showing oscillation frequency (*L*) and AUC (*M*). KCl was applied at 10 mmol/L. Corticosterone was applied at 20 nmol/L for 48 h. Traces in *F*, *H*, and *K* share the same F/F~min~ scale but are offset in the *y*-axis. Unless otherwise stated, data are mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 by one-way ANOVA (Bonferroni post hoc test). AU, arbitrary unit; Con, control; Cort, corticosterone; freq., frequency; G3, 3 mmol/L glucose; G11, 11 mmol/L glucose; G17, 17 mmol/L glucose; max, maximum; min, minimum; NS, nonsignificant.](db161356f1){#F1}

Supporting an action on later steps in ionic flux generation, 11-DHC and corticosterone reduced Ca^2+^ oscillation frequency at a moderately (11 mmol/L) elevated glucose concentration ([Fig. 1*F* and *G*](#F1){ref-type="fig"}). Glucocorticoids (cortisone and cortisol) also suppressed Ca^2+^ responses to glucose and glucose + 10 mmol/L KCl in human islets ([Fig. 1*H*--*J*](#F1){ref-type="fig"}), without significantly altering basal Ca^2+^ concentration ([Supplementary Table 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). The reported glucocorticoid actions were specific to glucose because both 11-DHC and corticosterone were unable to influence Ca^2+^ responses to exendin-4 in mouse islets in terms of oscillation frequency and AUC ([Fig. 1*K*--*M*](#F1){ref-type="fig"}), these parameters being the primary drivers of incretin-stimulated Ca^2+^ fluxes in this species ([@B23]).

β-Cells Remain Differentiated in the Presence of Glucocorticoids {#s14}
----------------------------------------------------------------

Immature or dedifferentiated β-cells fail to respond properly to glucose, a defect that can be partly explained by lowered transcription factor expression and impairments in metabolism and Ca^2+^ flux generation ([@B25]). This was unlikely to be the case here, however, because 11-DHC and corticosterone did not significantly affect mRNA abundance of the key β-cell maturity markers *Pdx1* ([Fig. 2*A*--*C*](#F2){ref-type="fig"}) and *Nkx6.1* ([Fig. 2*D*--*F*](#F2){ref-type="fig"}). Moreover, maximal ATP/ADP increases in response to glucose, measured by using the biosensor Perceval ([@B26]), were not significantly different ([Fig. 2*G* and *H*](#F2){ref-type="fig"}). 11-DHC and corticosterone did not affect the time to onset ([Supplementary Fig. 3*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)) or the amplitude ([Supplementary Fig. 3*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)) of the initial, transient decrease in ATP/ADP. No significant effects of glucocorticoid on basal or glucose-stimulated ATP levels were detected by luciferase-based assays ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). Patch-clamp electrophysiology revealed abnormal VDCC function in the presence of glucocorticoids, with voltage-current curves showing a marked reduction in Ca^2+^ conductance ([Fig. 2*I* and *J*](#F2){ref-type="fig"}). Suggestive of changes in VDCC function rather than expression, transcript levels of the major α− and β-subunits *Cacna1c (*[Fig. 2*K* and *L*](#F2){ref-type="fig"}), *Cacnb2* ([Fig. 2*M* and *N*](#F2){ref-type="fig"}), and *Cacna1d* ([Fig. 2*O* and *P*](#F2){ref-type="fig"}) were not significantly altered.

![Glucocorticoids impair VDCC function despite preserved β-cell identity and metabolism. *A*--*F*: Expression of mRNA for the β-cell maturity markers *Pdx-1* (*A*--*C*) and *Nkx6.1* (*D*--*F*) are similar in control and 11-DHC/corticosterone-treated islets (*n* = 4--7 animals, 48 h). *G*: Mean ± SEM traces showing no effect of glucocorticoids on maximal ATP/ADP responses to glucose measured using the biosensor Perceval. *H*: As for *G*, but summary bar graph showing the amplitude of ATP/ADP rises (*n* = 7 islets from four animals). *I*: 11-DHC and corticosterone reduce VDCC conductance as shown by the voltage-current relationship (*n* = 4 animals). *J*: As for *I*, but representative Ca^2+^ current traces. *K*--*P*: Expression levels of the VDCC α/β-subunits *Cacna1c* (*K* and *L*), *Cacnb2* (*M* and *N*), and *Cacna1d* (*O* and *P*) are not significantly altered by 11-DHC or corticosterone (*n* = 4--6 animals, 48 h). Corticosterone was applied at 20 nmol/L for 48 h. Unless otherwise stated, data are mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 for 11-DHC vs. control; \#*P* \< 0.05, \#\#*P* \< 0.01 for corticosterone vs. control (NS, nonsignificant) by Student *t* test, Student paired *t* test, or one-way ANOVA (Bonferroni post hoc test). Cort, corticosterone; G3, 3 mmol/L glucose; G17, 17 mmol/L glucose.](db161356f2){#F2}

Glucocorticoids Do Not Affect Insulin Secretory Responses {#s15}
---------------------------------------------------------

In response to glucose, increases in ATP/ADP ratios lead to closure of K~ATP~ channels, opening of VDCCs, and Ca^2+^-dependent insulin secretion ([@B27]). Thus, perturbed cytosolic Ca^2+^ fluxes/levels generally translate to reductions in insulin secretory output ([@B27]). However, glucose and glucose + KCl-stimulated insulin release were not significantly different after 48-h exposure of islets to 11-DHC or corticosterone ([Fig. 3*A*](#F3){ref-type="fig"}). This was not due to an increase in insulin expression because *Ins1* mRNA levels were similar in the presence of both glucocorticoids ([Fig. 3*B*--*D*](#F3){ref-type="fig"}). Likewise, total insulin content was not significantly different between treatments under all stimulation conditions examined ([Fig. 3*E*](#F3){ref-type="fig"}). Insulin secretion also was unaffected by cortisone and cortisol treatment in primary human islets ([Fig. 3*F* and *G*](#F3){ref-type="fig"} and [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)).

![Insulin secretion from islets is maintained in the face of excess glucocorticoid. *A*: Basal, glucose-stimulated, and glucose + KCl--stimulated insulin secretion is unaffected after 48-h treatment of mouse islets with either 11-DHC or corticosterone (*n* = 5 animals). *B*--*D*: Quantitative real-time PCR analysis of *Ins1* mRNA expression shows no significant changes in response to 11-DHC 20 nmol/L (*B*), 11-DHC 200 nmol/L (*C*), or corticosterone (*D*) (*n* = 4--7 animals). *E*: Total insulin content is unaffected by 11-DHC or corticosterone (*n* = 3 animals). *F*: Basal, glucose-stimulated, and glucose + KCl--stimulated insulin secretion is unaffected after 48-h treatment of human islets with either cortisone 200 nmol/L or cortisol 20 nmol/L (*n* = 3 donors). *G*: As for *F*, but stimulation index to better account for differences in basal secretion between islet batches from the various isolation centers. Corticosterone was applied at 20 nmol/L for 48 h. KCl was applied at 10 mmol/L. Unless otherwise stated, data are mean ± SD or range. \**P* \< 0.05, \*\**P* \< 0.01 by Student *t* test, one-way ANOVA (Bonferroni post hoc test), or two-way ANOVA. G3, 3 mmol/L glucose; G17, 17 mmol/L glucose; NS, nonsignificant.](db161356f3){#F3}

cAMP Signals Are Upregulated by Glucocorticoids {#s16}
-----------------------------------------------

Granule release competency can be increased by signals, including cAMP, which act directly upon protein kinase A (PKA) and Epac2 ([@B28]). By using the FRET probe Epac2-camps to dynamically report cytosolic cAMP ([@B20]), glucose induced a robust increase in levels of the nucleotide ([Fig. 4*A*](#F4){ref-type="fig"}). Both 11-DHC and corticosterone upregulated cAMP responses to glucose by ∼1.5-fold ([Fig. 4*A*--*C*](#F4){ref-type="fig"}). This appeared necessary for maintenance of secretory output because chemical inhibition of PKA significantly reduced glucose-stimulated insulin release in 11-DHC--treated islets ([Fig. 4*D*](#F4){ref-type="fig"}). Indeed, more granules were present at the membrane in glucocorticoid-treated islets, which was revealed by using superresolution structured illumination microscopy ([Fig. 4*E* and *F*](#F4){ref-type="fig"}). Similar results were seen in human islets, with cortisone and cortisol both augmenting cAMP responses to glucose ([Fig. 4*G* and *H*](#F4){ref-type="fig"}). As for Ca^2+^, the actions of glucocorticoid were glucose-specific because neither 11-DHC nor corticosterone altered cAMP responses to exendin-4 ([Fig. 4*I* and *J*](#F4){ref-type="fig"}). Supporting a central role for adenylate cyclase (Adcy) in this effect, expression of *Adcy1* was increased by both glucocorticoids ([Fig. 4*K* and *L*](#F4){ref-type="fig"}), and induction of lipotoxicity with palmitate (shown previously to lower *Adcy9* mRNA \[[@B29]\]) prevented glucocorticoid from augmenting cAMP responses to glucose ([Fig. 4*M* and *N*](#F4){ref-type="fig"}).

![Glucocorticoids potentiate cAMP signaling. *A*: Both 11-DHC and corticosterone amplify glucose-stimulated cAMP generation as measured online by using the biosensor Epac2-camps (forskolin \[FSK\] positive control; mean ± SEM traces shown; *n* = 20--24 islets from five animals). *B*: Summary bar graph showing significant effects of either glucocorticoid on the AUC of cAMP responses to glucose. *C*: Representative images of FRET responses in control-, 11-DHC--, and corticosterone-treated β-cells expressing Epac2-camps (scale bar = 10 μm). *D*: Inhibition of PKA decreases glucose-stimulated insulin secretion in the presence of 11-DHC but not control (mean and range shown; *n* = 3 animals). *E*: 11-DHC and corticosterone increase the fraction of the cell membrane occupied by insulin granules (V/v). *F*: Representative structured illumination microscopy images showing insulin granules in control-, 11-DHC--, and corticosterone-treated islets (*n* = 8 cells from three animals; scale bar = 5 μm; bottom panel shows zoom-in). *G*: Cortisone and cortisol augment glucose-stimulated cAMP generation in human islets (mean ± SEM traces shown). *H*: As for *G*, but summary bar graph showing AUC of cAMP responses to glucose (*n* = 10--11 islets from three donors). *I*: Glucocorticoid does not affect cAMP responses to exendin-4 (Ex4) 10 nmol/L (*n* = 24--46 islets from four animals). *J*: As for *I*, but summary bar graph showing AUC of cAMP responses. *K* and *L:* Relative (fold-change) expression levels of *Adcy1*, -*5*, -*6*, -*8*, and -*9* in 11-DHC-- (*K*) and corticosterone (*L*)-treated islets (*n* = 4--5 animals). *M*: Palmitate (Palm) but not BSA control prevents 11-DHC from augmenting cAMP responses to glucose (traces represent mean ± SEM; *n* = 23--27 islets from four animals). *N*: As for *M*, but summary bar graph showing AUC of cAMP responses. 11-DHC and corticosterone were applied for 48 h at 200 nmol/L and 20 nmol/L, respectively. Unless otherwise stated, data are mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 by Student *t* test or one-way ANOVA (with Bonferroni or Tukey post hoc test). AU, arbitrary unit; Cer/Cit, cerulean/citrine; Cort, corticosterone; G3, 3 mmol/L glucose; G11, 11 mmol/L glucose; G17, 17 mmol/L glucose; max, maximum; min, minimum; NS, nonsignificant.](db161356f4){#F4}

*Hsd11b1* Is Expressed in Islets of Langerhans {#s17}
----------------------------------------------

HSD11B1 is responsible for catalyzing the conversion of 11-DHC to corticosterone and is an important mechanism that determines local glucocorticoid activity ([@B30]). Expression of HSD11B1 in islets has been shown previously to be sufficient for 11-DHC→corticosterone conversion ([@B7]). We therefore repeated studies in islets obtained from mice globally lacking one (*Hsd11b1*^+/−^) or both (*Hsd11b1*^−/−^) alleles of *Hsd11b1*. Although *Hsd11b1* mRNA levels were low in mouse islets compared with liver and muscle, it was still detectable (ΔCt = 7.33 ± 1.80) ([Supplementary Fig. 5*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). Moreover, *Hsd11b1* mRNA abundance was 55--75% lower in islets from animals expressing a single copy of *Hsd11b1* and undetectable in those deleted for both alleles ([Supplementary Fig. 5*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), as assessed by specific TaqMan assays. Quantification of *HSD11B1* mRNA revealed similar levels in human and mouse islets, with expression an order of magnitude lower than in human subcutaneous and omental adipose tissue ([Supplementary Fig. 5*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), a major site of enzyme activity and steroid reactivation ([@B31]).

*Hsd11b1* Deletion Reverses the Effects of Glucocorticoids on β-Cell Ca^2+^ and cAMP Signaling {#s18}
----------------------------------------------------------------------------------------------

As expected, both 11-DHC and corticosterone impaired cytosolic Ca^2+^ fluxes in β-cells residing within islets from *Hsd11b1*^+/−^ animals ([Fig. 5*A*--*D*](#F5){ref-type="fig"} and [Supplementary Fig. 6*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). However, deletion of *Hsd11b1* throughout the islet reversed these effects, with 11-DHC and corticosterone no longer able to suppress Ca^2+^ rises in response to glucose or glucose + KCl ([Fig. 5*E*--*H*](#F5){ref-type="fig"} and [Supplementary Fig. 6*C* and *D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). This suggests that local regulation of glucocorticoid activity in the islet may mediate the effects of 11-DHC and corticosterone on β-cell Ca^2+^ fluxes. 11-DHC was able to significantly elevate cAMP responses to glucose in *Hsd11b1*^+/−^ ([Fig. 6*A*--*D*](#F6){ref-type="fig"} and [Supplementary Fig. 7*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)) but not *Hsd11b1*^−/−^ islets ([Fig. 6*E*--*H*](#F6){ref-type="fig"} and [Supplementary Fig. 7*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). However, corticosterone still improved cAMP responses to glucose, even after deletion of *Hsd11b1* ([Fig. 6*A*--*H*](#F6){ref-type="fig"} and [Supplementary Fig. 7*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)). Glucose-stimulated insulin secretion was significantly higher in corticosterone- versus control- or 11-DHC--treated *Hsd11b1*^−/−^ islets ([Fig. 6*I*](#F6){ref-type="fig"}), consistent with the Ca^2+^ and cAMP results. Similarly, quantitative real-time PCR analyses revealed upregulation of *Adcy1* expression by corticosterone but not by 11-DHC in *Hsd11b1*^−/−^ islets ([Fig. 6*J* and *K*](#F6){ref-type="fig"}). Ca^2+^ responses to glucose, glucose + KCl, and KCl were not significantly decreased by 11-DHC ([Fig. 7*A*--*F*](#F7){ref-type="fig"} and [Supplementary Fig. 8*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)) in islets pretreated with RU486. Similarly, corticosterone was unable to impair Ca^2+^ responses to glucose in RU486-treated islets ([Fig. 7*E*](#F7){ref-type="fig"} and [Supplementary Fig. 8*C* and *D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), although Ca^2+^ responses to glucose + KCl were unaffected ([Fig. 7*F*](#F7){ref-type="fig"}). Thus, the inhibitory actions of the glucocorticoids are partly mediated by the GR.

![Deletion of *Hsd11b1* reverses the effects of glucocorticoids on Ca^2+^ signaling. *A*: Mean intensity-over-time traces showing a reduction in glucose- and glucose + KCl--stimulated Ca^2+^ rises in *Hsd11b1*^+/−^ islets treated for 48 h with 11-DHC or corticosterone (*n* = 15--19 islets from three animals). *B* and *C*: As for *A*, but summary bar graphs showing the amplitude of Ca^2+^ responses to glucose (*B*) and glucose + KCl (*C*). *D*: Representative maximum intensity projection images showing impaired glucose-stimulated Ca^2+^ rises in 11-DHC-- and corticosterone- vs. control-treated *Hsd11b1*^+/−^ islets (scale bar = 20 μm) (images cropped to show a single islet). *E*: Mean ± SEM intensity-over-time traces showing intact glucose- and glucose + KCl--stimulated Ca^2+^ rises in *Hsd11b1*^−/−^ islets treated for 48 h with 11-DHC or corticosterone (*n* = 19--28 islets from three animals). *F* and *G*: As for *E*, but summary bar graphs showing the amplitude of Ca^2+^ responses to glucose (*F*) and glucose + KCl (*G*). *H*: Representative maximum intensity projection images showing similar glucose-stimulated Ca^2+^ rises in 11-DHC-- and corticosterone- vs. control-treated *Hsd11b1*^−/−^ islets (scale bar = 20 μm) (images cropped to show a single islet). 11-DHC and corticosterone were applied for 48 h at 200 nmol/L and 20 nmol/L, respectively. KCl was applied at 10 mmol/L. Unless otherwise stated, data are mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 by one-way ANOVA (Bonferroni post hoc test). Con, control; Cort, corticosterone; G3, 3 mmol/L glucose; G17, 17 mmol/L glucose; max, maximum; min, minimum; NS, nonsignificant.](db161356f5){#F5}

![Deletion of *Hsd11b1* reverses the effects of 11-DHC on cAMP signaling. *A*: Mean ± SEM intensity-over-time traces showing cAMP responses to glucose in 11-DHC-- and corticosterone-treated *Hsd11b1*^+/−^ islets (forskolin \[FSK\] positive control; *n* = 15--19 islets from three animals). *B* and *C*: As for *A*, but summary bar graphs showing the amplitude (*B*) and AUC (*C*) of cAMP responses. *D*: Representative images of cAMP responses to glucose in control-, 11-DHC--, or corticosterone-treated *Hsd11b1*^+/−^ islets expressing Epac2-camps (scale bar = 10 μm). *E*: Mean ± SEM intensity-over-time traces showing that cAMP responses to glucose are potentiated by corticosterone but not 11-DHC in *Hsd11b1*^−/−^ islets (*n* = 22--23 islets from three animals). *F* and *G*: As for *E*, but summary bar graphs showing the amplitude (*F*) and AUC (*G*) of cAMP responses. *H*: Representative images of cAMP responses to glucose in control-, 11-DHC--, and corticosterone-treated *Hsd11b1*^−/−^ islets expressing Epac2-camps (scale bar = 10 μm). *I*: Insulin secretion in response to glucose is significantly improved in corticosterone- vs. control- and 11-DHC--treated *Hsd11b1*^−/−^ islets (*n* = 4 animals). *J* and *K*: Relative (fold-change) expression levels of *Adcy1*, -*5*, -*6*, -*8*, and -*9* in 11-DHC-- (*J*) and corticosterone (*K*)-treated *Hsd11b1*^−/−^ islets (*n* = 5 animals). 11-DHC and corticosterone were applied for 48 h at 200 nmol/L and 20 nmol/L, respectively. KCl was applied at 10 mmol/L. Unless otherwise stated, data are mean ± S.D. \**P* \< 0.05, \*\**P* \< 0.01 by Student *t* test or one-way ANOVA (Bonferroni post hoc test). AU, arbitrary unit; Cer/Cit, cerulean/citrine; Con, control; Cort, corticosterone; G3, 3 mmol/L glucose; G17, 17 mmol/L glucose; max, maximum; min, minimum; NS, nonsignificant.](db161356f6){#F6}

![11-DHC effects are mediated through the GR. *A*: The GR antagonist RU486 prevents the suppressive effects of 11-DHC on glucose- and glucose + KCl--stimulated Ca^2+^ signals (mean ± SEM traces shown; *n* = 12--13 islets from four animals). *B* and *C*: As for *A,* but summary bar graphs showing that 11-DHC does not affect Ca^2+^ responses to glucose (*B*) or glucose + KCl (*C*) in RU486-treated islets. *D*: Representative maximum intensity projection images showing impaired Ca^2+^ rises in 11-DHC--treated islets, which can be reversed by using the GR antagonist RU486 (scale bar = 20 μm) (images cropped to show a single islet). *E*: RU486 blocks the effects of corticosterone on Ca^2+^ responses to glucose (*n* = 14--17 islets from six animals). *F*: As for *E*, but RU486 is unable to significantly affect Ca^2+^ responses to glucose + KCl in corticosterone-treated islets (*n* = 14--17 islets from six animals). 11-DHC and corticosterone were applied for 48 h at 200 nmol/L and 20 nmol/L, respectively. KCl was applied at 10 mmol/L. Unless otherwise stated, data are mean ± SD. \**P* \< 0.05, \*\**P* \< 0.01 by one-way ANOVA (Bonferroni post hoc test). Islets were pretreated with 1 μmol/L RU486. Con, control; Cort, corticosterone; G3, 3 mmol/L glucose; G17, 17 mmol/L glucose; max, maximum; min, minimum; NS, nonsignificant.](db161356f7){#F7}

Discussion {#s19}
==========

We show that corticosterone and cortisol and their less-active precursors 11-DHC and cortisone impair glucose-, glucose + KCl--, and KCl-stimulated ionic fluxes in rodent and human β-cells. However, insulin secretory output is likely preserved because both glucocorticoids upregulate cAMP signals to increase insulin granule number at the membrane. Invoking a critical role for glucocorticoid interconversion, the effects of 11-DHC could be prevented after islet-wide deletion of *Hsd11b1*. Thus, an enzyme-assisted steroid-regulated feedback loop maintains insulin secretion in the face of altered β-cell ionic signaling ([Fig. 8](#F8){ref-type="fig"}).

![Glucocorticoids impair K~ATP~-independent signals to reduce ionic fluxes in glucose-stimulated β-cells. This is further exacerbated by HSD11B1, which increases availability of more active glucocorticoid (11-DHC/cortisone→corticosterone/cortisol) in a paracrine manner. However, insulin secretion is preserved because glucocorticoids reprogram the β-cell signaling cassette toward a cAMP phenotype most likely through upregulation of specific Adcy isoforms.](db161356f8){#F8}

Both corticosterone and 11-DHC have previously been shown to exert inhibitory effects on insulin release ([@B6],[@B7],[@B10],[@B11]). However, these studies either used islets from *ob/ob* mice that display highly upregulated *Hsd11b1* expression ([@B6],[@B10]) or incubated wild-type islets with glucocorticoid for only 2 h ([@B7],[@B11]), which is unlikely to fully compensate for the loss of adrenal input that occurs after islet isolation. Likewise, studies in which glucocorticoids are administered in the drinking water are confounded by insulin resistance and compensatory islet expansion ([@B12]). Thus, the effects observed in the current study more likely reflect the cellular/molecular actions of circulating glucocorticoids under normal conditions.

Cytosolic Ca^2+^ responses to glucose were impaired in the presence of either 11-DHC or corticosterone, which was unlikely caused by defects in metabolism and K~ATP~ channel function because glucose-induced ATP/ADP maximal rises were unaffected. However, KCl- and KCl + glucose--induced Ca^2+^ influx as well as VDCC conductance were markedly suppressed, although quantitative real-time PCR analyses of expression levels of the key L-type VDCC subunits showed no differences. Paradoxically, glucocorticoid improved the sustained Ca^2+^ responses to 3 mmol/L glucose + 10 mmol/L KCl. Although this may reflect basal cAMP generation as a result of upregulated *Adcy1*, VDCCs do not open fully under these conditions ([Supplementary Table 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db16-1356/-/DC1)), meaning that true defects in their activity are likely to be missed. Indeed, glucocorticoids may induce changes that only restrict Ca^2+^ entry when VDCC open probability increases to support insulin secretion (i.e., 17 mmol/L glucose and/or 30 mmol/L KCl). Ca^2+^ oscillation frequency also was affected, suggesting that glucocorticoids may conceivably target more distal steps in Ca^2+^ flux generation such as intracellular stores (e.g., by depleting them through cAMP sensitization of IP~3~ receptors \[[@B32]\]), upregulate ion channels involved in voltage inactivation (i.e., large-conductance Ca^2+^-activated K^+^ channels \[[@B33]\]), or alter glucose-regulated inputs other than cAMP ([@B34]). These effects are presumably specific to glucose-stimulated Ca^2+^ rises because responses to the incretin mimetic exendin-4 remained unchanged by glucocorticoid exposure, possibly secondary to PKA-mediated rescue of VDCC function or organellar Ca^2+^ release ([@B35]).

Recent RNA sequencing analyses of purified mouse β-cells have shown that *Hsd11b1* mRNA levels are unusually low in these and other islet endocrine cells (i.e., it is an islet disallowed gene) ([@B36]). Likewise, *HSD11B1* levels were low in human β- and α-cells ([@B37]). These findings contrast with reports that protein expression colocalizes with glucagon or insulin in rodent islets depending on the antibody used ([@B7],[@B38]). The reasons for these discrepancies are unclear, but in the current study, specific TaqMan assays showed consistently detectable mRNA levels in both rodent and human islets. Moreover, 11-DHC effects could be prevented in global *Hsd11b1*^−/−^ islets in which mRNA was largely absent and *HSD11B1* expression in human islets is only an order of magnitude lower than in adipose tissue, a major site for steroid reactivation after the liver ([@B31]). Thus, 11-DHC likely affects β-cell function in a paracrine manner, possibly through the actions of HSD11B1 in nonendocrine islet cell types (e.g., endothelial cells where expression levels are higher \[[@B37]\]). This may form the basis of an adaptive mechanism to prevent the build-up of high local corticosterone/cortisol concentrations. Together, these data highlight the importance of the islet context for the regulation of insulin secretion and underline the requirement to consider cell-cell cross talk when assessing the functional consequences of β-cell gene disallowance.

Global deletion of *Hsd11b1* prevented the effects of 11-DHC on ionic and cAMP fluxes, as expected, suggesting that local regulation of glucocorticoid activity is important for β-cell function. However, corticosterone was unable to impair Ca^2+^ responses in *Hsd11b1*^−/−^ islets, whereas potentiation of cAMP remained intact. Together, these observations raise the possibility that corticosterone may undergo substantial oxidation to 11-DHC through HSD11B2 ([@B37]), with local concentrations dropping below the threshold for suppression of Ca^2+^ but not cAMP after *Hsd11b1* knockout. Although previous studies have shown that a single *Hsd11b1* allele is sufficient for full enzymatic activity ([@B39]), additional studies are required to determine whether this is also the case in islets.

Consistent with upregulated cAMP signaling, an increase in the number of submembrane insulin granules was observed in glucocorticoid-treated islets. cAMP has been shown to recruit nondocked insulin granules to the membrane as well as to increase the size of the readily-releasable granule pool through Epac2 and PKA ([@B40],[@B41]), and this may account for the intact secretory responses to glucose and KCl. The exact mechanisms by which 11-DHC and corticosterone boost cAMP signaling are unknown but likely involve specific adenylate cyclases because *Adcy1* gene expression was increased in 11-DHC-- and corticosterone-treated islets compared with controls. Moreover, palmitate, which downregulates *Adcy9* and impairs cAMP responses to glucose ([@B29]), prevented 11-DHC from increasing cAMP levels. Although *Adcy9* mRNA expression was not significantly affected by glucocorticoid, other mechanisms can account for cAMP generation, including organization of the enzyme into microdomains ([@B42]). Pertinently, knockdown of *Adcy1* and *Adcy9* has been shown to reduce glucose-stimulated cAMP rises and insulin secretion in β-cells ([@B29],[@B43]). Additional studies thus are warranted in glucocorticoid-treated *Adcy1-* and *Adcy9*-null islets. Upregulated cAMP signaling may represent a protective mechanism that is disrupted by free fatty acids to induce β-cell failure/decompensation in the face of excess glucocorticoid. Of note, endogenous elevation of glucocorticoids leads to dyslipidemia as a result of lipolysis, de novo fatty acid production/turnover, and hepatic fat accumulation ([@B44]).

In mouse islets, cAMP responses to glucose have been shown to be oscillatory ([@B29]), albeit noisier than those in MIN6/INS-1E cells ([@B45]). However, the latter study used total internal reflection fluorescence microscopy to study submembrane cAMP responses, whose changes may be larger and more dynamic than those recorded throughout the cytosol ([@B46]). Similar studies that used epifluorescence techniques showed nonoscillatory cAMP increases in response to high glucose concentrations ([@B47]). Thus, additional studies are required to investigate the impact of glucocorticoids on cAMP oscillations, which were not detectable at the axial resolutions used here. Although ATP/ADP responses were oscillatory in single islets, a transient dip was present after introduction of high glucose. This has also been seen in previous studies ([@B19]) and may reflect net ATP consumption secondary to Ca^2+^ transporter activity ([@B48]), glucokinase activity ([@B49]) and the initial steps of exocytosis ([@B50]), or an uncoupling effect of highly elevated Ca^2+^ levels on mitochondrial function ([@B21]). Although similar results were seen with luciferase-based ATP measures, a change in intracellular pH and Perceval intensity cannot be excluded.

In summary, we have identified a novel mechanism by which glucocorticoids maintain β-cell function in rodent and human β-cells through engagement of parallel cAMP pathways. Failure of this protective feedback loop may contribute to impaired insulin release during states of glucocorticoid excess (e.g., Cushing syndrome).
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**Acknowledgments.** The authors thank Gary Yellen (Harvard University) for providing the plasmid for Perceval. They also thank Dr. Jocelyn E. Manning Fox and Patrick E. MacDonald for provision of human islets through the Alberta Diabetes Institute IsletCore at the University of Alberta with the assistance of the Human Organ Procurement and Exchange program, Trillium Gift of Life Network, and other Canadian organ procurement organizations. The authors are grateful to the European Consortium for Islet Transplantation (ECIT), which was supported by JDRF award 31-2008-416 (ECIT Islet for Basic Research program).

**Funding.** N.C.V. and D.A.J. were supported by National Institutes of Health grant R01-DK-097392 and American Diabetes Association grant 1-17-IBS-024. P.M. and M.B. were supported by the Innovative Medicine Initiative Joint Undertaking under grant agreement no. 155005 (iMiDiA), resources of which comprised financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and in-kind contributions from European Federation of Pharmaceutical Industries and Associations companies, and by the Italian Ministry of Education, University and Research (PRIN 2010-2012). L.P. provided human islets through collaboration with the Diabetes Research Institute, San Raffaele Scientific Institute (Milan, Italy), within the European islet distribution program for basic research supported by JDRF (1-RSC-2014-90-I-X). G.A.R. was supported by Wellcome Trust Senior Investigator (WT098424AIA) and Royal Society Wolfson Research Merit awards and by Medical Research Council (MRC) Programme (MR/J0003042/1), Biological and Biotechnology Research Council (BB/J015873/1), and Diabetes UK project (11/0004210) grants. G.A.R. and D.J.H. were supported by an MRC project grant (MR/N00275X/1). G.G.L. was supported by a Wellcome Trust Senior Research Fellowship (104612/Z/14/Z). D.J.H. was supported by a Diabetes UK R.D. Lawrence grant (12/0004431), European Foundation for the Study of Diabetes (EFSD)/Novo Nordisk Rising Star Fellowship, and Wellcome Trust Institutional Support Award. This project has received funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (Starting Grant 715884 to D.J.H.).

**Duality of Interest.** No potential conflicts of interest relevant to this article were reported.

**Author Contributions.** N.H.F.F. conceived and devised the study, performed the experiments, and analyzed data. C.L.D., Y.S.E., N.C.V., and D.A.J. performed experiments and analyzed data. P.M., M.B., R.N., and L.P. isolated and provided human islets. G.A.R. provided reagents. G.G.L. provided reagents and analyzed data. D.J.H. supervised the research, conceived and devised the study, performed analyses, and wrote the manuscript with input from all authors. D.J.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** Parts of this study were presented in abstract form at the 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal, 11--15 September 2017.
